← All stocks

Amylyx Pharmaceuticals, Inc.

AMLX Net selling

CIK 0001658551 #1444 in the set updated 17 Sep 2026

Bought (120 mo)

$50.25M

out of their own pocket, the only kind of buying there is

Sold (120 mo)

$91.58M

$933.36K on a plan · $6.49M straight out of an exercise

Sold at will

$84.15M

117 of 132 sales

Net

−$41.33M

−$33.90M against sales at will

By person

16 insiders · 161 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Morningside Venture Investments Ltd entity

10% owner

$5.00M (1)

$22.54M (17)

−$17.54M

4,997,302

4.48%

$165.65M

—

Klee Justin B.

Co-Chief Executive Officer

—

$7.82M (20)

−$7.82M

3,613,056

3.24%

$119.77M

+46.1%

Cohen Joshua B

Co-Chief Executive Officer

—

$7.82M (20)

−$7.82M

3,613,123

3.24%

$119.77M

+46.1%

Yeramian Patrick D

Chief Medical Officer

—

$3.72M (8) scheduled

−$3.72M

205,605

0.1845%

$6.82M

−8.0%

FRATES JAMES M

Chief Financial Officer

$101.37K (1)

$2.83M (15)

−$2.73M

284,697

0.2555%

$9.44M

—

VIKING GLOBAL INVESTORS LP entity

10% owner

$43.70M (1)

$41.72M (16)

+$1.98M

1,850,940

1.66%

$61.36M

—

Mazzariello Gina

Chief Legal Officer

—

$1.87M (20) scheduled

−$1.87M

190,838

0.1713%

$6.33M

—

ALS Invest 1 B.V.

10% owner

—

$1.25M (4)

−$1.25M

5,895,280

5.29%

$195.42M

—

Bedrosian Camille L

Chief Medical Officer

—

$798.66K (8)

−$798.66K

278,064

0.2496%

$9.22M

—

MILNE GEORGE M JR

Director

$719.79K (2)

$1.12M (2)

−$396.29K

812,881

0.7295%

$26.95M

−6.6%

Firestone Karen

Director

$350.64K (5)

—

+$350.64K

116,900

0.1049%

$3.88M

—

Cheng Isaac

Director

$124.98K (1)

—

+$124.98K

10,422,228

9.35%

$345.48M

—

FONTEYNE PAUL R.

Director

$74.99K (1)

—

+$74.99K

3,947

0.0035%

$130.84K

—

Olinger Margaret

Chief Commercial Officer

$130.00K (1)

$87.23K (2)

+$42.77K

276,108

0.2478%

$9.15M

+56.2%

Zeiher Bernhardt G

Director

$37.01K (1)

—

+$37.01K

10,000

0.0090%

$331.49K

—

Quimi Daphne

Director

$9.44K (2)

—

+$9.44K

5,000

0.0045%

$165.74K

—

Individual transactions

Insider

Date

Role

Action

Price

Amount

Klee Justin B.

16 Jan 2026

Co-Chief Executive Officer

Sold after exercise

1,995

$13.89

$27.70K

Cohen Joshua B

16 Jan 2026

Co-Chief Executive Officer

Sold after exercise

1,974

$13.83

$27.30K

Klee Justin B.

15 Jan 2026

Co-Chief Executive Officer

Sold after exercise

136,193

$13.58

$1.85M

Cohen Joshua B

15 Jan 2026

Co-Chief Executive Officer

Sold after exercise

136,193

$13.59

$1.85M

FRATES JAMES M

16 May 2023

Chief Financial Officer

Sold after exercise

500

$27.60

$13.80K

FRATES JAMES M

16 May 2023

Chief Financial Officer

Sold after exercise

32,000

$26.93

$861.65K

Yeramian Patrick D

15 May 2023

Chief Medical Officer

Sold after exercise

11,965

$29.03

$347.36K

Yeramian Patrick D

17 Apr 2023

Chief Medical Officer

Sold after exercise

300

$30.94

$9.28K

Yeramian Patrick D

17 Apr 2023

Chief Medical Officer

Sold after exercise

49,279

$30.53

$1.50M

Show all 161 transactions →

What was left out

Form 4 filings counted 177

Amendments (4/A) skipped 5

Filings about a different issuer 0

Unreadable filings 0

Joint filings 2

Sales on a Rule 10b5-1 plan 6

Sales straight out of an exercise 9

Sales at will 117

Transactions with no price 0

Shares from compensation/vesting 38,287,796

Sales filed before the plan box existed 42

History held since 10 Jan 2022